New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Nusinersen was generally well tolerated with no new safety concerns identified with eight years of follow-up. All participants had at least one AE, the majority of which were mild to moderate in ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Spinraza, also known as nusinersen, is a medicine used to treat spinal muscular atrophy (SMA) in children and adults. SMA is a genetic disease that is passed down through families. It leads to ...

Spinraza is used to treat spinal muscular atrophy (SMA) in adults and children of any age.. About SMA and its types. SMA is a group of rare genetic disorders. It involves the loss of motor neurons ...

Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.

--Ionis Pharmaceuticals today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA ® in infants and toddlers living with spinal muscular atrophy.